Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3505-3511

  Kornmann, Marko ^a   Danenberg, Kathleen D ^b   Arber, Nadir ^c   Beger, Hans G ^d   Danenberg, Peter V ^b   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; FLOXURIDINE; FLUOROURACIL; MESSENGER RNA; MITOXANTRONE; PHOSPHOTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FLOXURIDINE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033565625     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. 1 events and regulation of cell proliferation. Science (Washington DC), 246: 603-608, 1989.
2. 1 phase progression: cyclin on cue. Cell, 79: 551-555, 1994.
3. 1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8: 3447-3457, 1993.
4. 1 phase in rodent fibroblasts. Genes Dev., 7: 1559-1571, 1993.
5. 1 and E with an inducible system. Mol. Cell. Biol., 14: 1669-1679, 1994.
6. 1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene, 11: 571-580, 1995.
7. 1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57: 1569-1574, 1997.
8. Schrump, D. S., Chen, A., and Consoli, U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Therapy, 3: 131-135, 1996.
9. 1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J. Clin. Invest., 101: 344-352, 1998.
10. Hall, M., and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68: 67-108, 1996.
11. Motokura, T., and Arnold, A. Cyclins and oncogenesis. Biochim. Biophys. Acta, 1155:63-78, 1993.
12. 1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
13. 1 mRNA and antigen in esophageal cancer. Am. J. Pathol., 146: 1161-1169, 1995.
14. 1 overexpression and prognosis in colorectal adenocarcinoma. Oncology, 55: 145-151, 1998.
15. 1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57: 1634-1637, 1997.
16. Kornmann, M., Ishiwata, T., Itakura, J., Tangvoranuntakul, P., Beger, H. G., and Korc, M. Oncology, 55. 363-369, 1998.
17. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
18. Korc, M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. North Am., 7: 25-41, 1998.
19. Link, K. H., Leder, G., Formentini, A., Fortnagel, G., Kornmann, M., Schatz, M., and Beger, H. G. Surgery and multimodal treatments in pancreatic cancer - a review on the basis of future multimodal treatment concepts. Gan To Kagaku Ryoho, 26: 10-40, 1999.
20. Kornmann, M., Ishiwata, T., Beger, H. G., and Korc, M. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine events. Oncogene, 15: 1417-1424, 1997.
21. Raitano, A. B., and Korc, M. Tumor necrosis factor up-regulates γ-interferon binding in a human carcinoma cell line. J. Biol. Chem., 265: 10466-10472, 1990.
22. Baldwin, R. L., and Korc, M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor β-1. Growth Factors, 8: 23-34: 1993.
23. Lockey, C., Otto, E., and Long, Z. Real-time fluorescence detection of a single DNA molecule. Biotechniques, 24: 744-746, 1998.
24. Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Volkenandt, M., Shea, L. C. C., Aigner, K., Gustavsson, B., Leichman, L., Frösing, R., Ray, M., Gibson, N. W., Spears, C. P., and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
25. Lenz, H-J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Laine, L., Crooks, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1995.
26. Johnston, P. G., Lenz, H-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55; 1407-1412, 1995.
27. Kuo, D. Y-S., Mallick, S., Shen, H-J., DeVictoria, C., Jones, J., Fields, A. L., Goldberg, G. L., Runowicz, C. D., and Horwitz, S. B. Analysis of MDR1 expression in normal and malignant endometrium by reverse Iranscription-polymerase chain reaction and immunohistochemistry. Clin. Cancer Res., 2: 1981-1992, 1996.
28. Kornmann, M., Link, K. H., Lenz, H-J., Pillasch, J., Metzger, R., Butzer, U., Leder, G. H., Weindel, M., Safi, F., Danenberg, K. D., Beger, H. G., and Danenberg, P. V. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett., 118: 29-35, 1997.
29. Livak, K. J., Flood, S. J., Marmaro, J., Giusti, W., and Deetz, K. Oligonucleotides with fluorescent dyes at opposite ends provides a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl., 4: 357-362, 1995.
30. Gros, P., Neriah, Y. B., Croop, J. M., and Housman, D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (Lond.), 323: 728-731, 1986.
31. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
32. Johnston, P. G., and Allegra, C. Colorectal cancer biology: clinical implications. Semin. Oncol., 22: 418-432, 1995.
33. Peters, G. J., van der Wilt, C. L., van Triest, B., Codacci-Pisanelli, G., Johnston, P. G., van Groeningen, C. J., and Pinedo, H. M. Thymidylate synthase and drug resistance. Eur. J. Cancer, 31A: 1299-1305, 1995.
34. Schwartz, E. L., Baptiste, N., Wadler, S., and Makower, D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem., 270: 19073-19077, 1995.
35. Kato, Y., Matsukawa, S., Muraoka, R., and Tanigawa, N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br. J. Cancer, 75: 506-511, 1997.
36. Schwartz, E. L., Hoffman, M., O'Connor, C. J., and Wadler, S. Stimulation of 5-fluorouracil metabolic activation by interferon-A in human colon carcinoma cells. Biochem. Biophys. Res. Commun., 182: 1232-1239, 1992.
37. Elias, S., and Sandoval, J. M. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biophys. Biochem. Res. Commun., 163: 867-874, 1989.
38. Eda, H., Fujimoto, K., Watanabe, S., Ura, M., Hino, A., Tanaka, Y., Wada, K., and Ishitsuka, H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32: 333-338, 1993.
39. Van der Graaf, W. T., de Vries, E. G., Timmer-Bosscha, H., Meersma, G. J., Mesander, G., Vellenga, E., and Mulder, N. H. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res., 54: 5368-5373, 1994.
40. Zhou, D. C., Ramond, S., Viguie, F., Faussat, A. M., Zittoun, R., and Marie, J. P. Sequential emergence of MRP-and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Int. J. Cancer, 65: 365-371, 1996.
41. Schurr, E., Raymond, M., Bell, J. C., and Gros, P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res., 49: 2729-2733, 1989.
42. Harris, A. L., and Hochhauser, D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol., 31: 205-213, 1992.
43. Hochhauser, D., Schnieders, B., Ercikan-Abali, E., Gorlick, R., Muise-Helmericks, R., Li, W. W., Fan, J., Banerjee, D., and Bertino, J. R. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J. Natl. Cancer Inst., 88: 1269-1275, 1996.
44. Link, K. H., Leder, G., Pillasch, J., Butzer, U., Staib, L., Kornmann, M., Bruckner, U., and Beger, H. G. in vitro concentration response studies and in vitro Phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin. Surg. Oncol., 14: 189-201, 1998.
45. Santi, D. V., McHenry, C. S., and Sommer, H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13: 471-481, 1974.
46. Zimmerman, M., and Seidenberg, J. Deoxyribosyl transfer. 1. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J. Biol. Chem., 230: 2618-2621, 1964.
47. Iltzsch, M. H., el Kouni, M. H., and Cha, S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry, 24: 6799-6807, 1985.
48. O'Brien, T. S., Fox, S. B., Dickinson, A. J., Turley, H., Westwood, M., Moghaddam, A., Gatter, K. C., Bicknell, R., and Harris, A. L. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res., 56: 4799-4804, 1996.
49. Santelli, G., and Valeriote, F. In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J. Natl. Cancer Inst., 64: 69-72, 1980.
50. Horikoshi, T., Danenberg, K. D., Stadibauer, T. H., Volkenandt, M., Shea, L. C., Aigner, K., Gustavsson, B., Leichman, L., Frösing, R., Ray, M, and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
51. Ju, J., Kane, S. E., Lenz, H. J., Danenberg, K. D., Chu E., and Danenberg, P. V. Desensitization and sensitization of cells to fluoropyrimidines with different anti-senses directed against thymidylate synthase messenger RNA. Clin. Cancer Res. 4: 2229-2236, 1998.
52. Thomas, X., and Archimbaud, E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol. Cell Ther., 39: 63-74, 1997.
53. Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
54. Riordan, J. R., and Ling, V. Genetic and biochemical characterization of multidrug resistance. Pharmacol. Ther., 28: 51-75, 1985.
55. Deeley, R. G., and Cole, S. P. Function, evolution and structure of multidrug resistance protein (MRP). Semin. Cancers Biol., 8: 193-204, 1997.